Pharming Group NV (PHAR)

Currency in EUR
1.012
+0.006(+0.55%)
Real-time Data·
PHAR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.0091.017
52 wk Range
0.8341.818
Key Statistics
Prev. Close
1.006
Open
1.01
Day's Range
1.009-1.017
52 wk Range
0.834-1.818
Volume
794.89K
Average Vol. (3m)
9.8M
1-Year Change
-16.6254%
Book Value / Share
0.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHAR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Pharming Group NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy38.00+3,658.65%37.00MaintainAug 03, 2026
Oppenheimer
Buy39.00+3,757.57%40.00MaintainJul 30, 2026
Oppenheimer
Buy40.00+3,856.48%41.00MaintainMay 08, 2026
Canaccord
Buy37.00+3,559.74%-New CoverageApr 10, 2026
Oppenheimer
Buy41.00+3,955.39%42.00MaintainMar 13, 2026

Pharming Group NV Earnings Call Summary for Q2/2026

  • Q2 revenue of $90.2M missed estimates by 10.94%; shares plunged 22% to $0.855, near 52-week low of $0.834 amid investor concerns.
  • RUCONEST sales fell 10% YoY to $72.3M due to competition; JOENJA grew 40% YoY to $17.9M but couldn't offset legacy product decline.
  • Full-year 2026 revenue guidance cut $30M to $375M-$395M range, implying 0-5% growth; operating expenses reduced $15M to $315M-$320M.
  • Management expects RUCONEST stabilization in H2 2026, JOENJA growth continuing at high-30% rate, with Japan launch set for August 2026.
  • CEO highlighted pipeline potential with two Phase II studies in immunodeficiencies reporting Q4; CVID opportunity could expand JOENJA to $1B+ blockbuster.
Last Updated: 07/30/2026, 08:34 AM
Read Full Transcript
Pharming Group investor slides for Q2/2026
Pharming Q2 2026 slides
Last Update: Jul 30, 2026
See full investor slides

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
-- / 0.06
Revenue / Forecast
90.2M / 101.28M
EPS Revisions
Last 90 days

PHAR Income Statement

Compare PHAR to Peers and Sector

Metrics to compare
PHAR
Peers
Sector
Relationship
P/E Ratio
90.1x−3.3x−0.4x
PEG Ratio
0.460.150.00
Price / Book
3.1x1.7x2.6x
Price / LTM Sales
2.3x3.8x3.1x
Upside (Analyst Target)
131.6%116.2%46.0%
Fair Value Upside
Unlock9.0%5.3%Unlock

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Employees
407

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
44.38M6.27%43.80M
Other Institutional Investors
142.65M20.15%140.76M
Public Companies & Retail Investors
520.75M73.58%513.88M
Total
707.78M100.00%698.44M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.3.02%21,354,46321,073
Arrowstreet Capital, Limited Partnership2.99%21,159,84620,881

People Also Watch

14.39
OVH
+3.45%
18.48
WEHA
-0.11%
3.02
ALCLS
-0.33%
0.1248
SIGHT
+5.76%

FAQ

What Is the Pharming Group (PHAR) Stock Price Today?

The Pharming Group stock price today is 1.012 EUR.

What Stock Exchange Does Pharming Group Trade On?

Pharming Group is listed and trades on the Amsterdam Stock Exchange.

What Is the Stock Symbol for Pharming Group?

The stock symbol for Pharming Group is "PHAR."

What Is the Pharming Group Market Cap?

As of today, Pharming Group market cap is 715.570M EUR.

What Is Pharming Group's Earnings Per Share (TTM)?

The Pharming Group EPS (TTM) is 0.013.

When Is the Next Pharming Group Earnings Date?

Pharming Group will release its next earnings report on Jul 30, 2026.

From a Technical Analysis Perspective, Is PHAR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Pharming Group Stock Split?

Pharming Group has split 2 times.

How Many Employees Does Pharming Group Have?

Pharming Group has 407 employees.

What is the current trading status of Pharming Group (PHAR)?

As of Aug 27, 2026, Pharming Group (PHAR) is trading at a price of 1.012 EUR, with a previous close of 1.006 EUR. The stock has fluctuated within a day range of 1.009 EUR to 1.017 EUR, while its 52-week range spans from 0.834 EUR to 1.818 EUR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.